secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-038003
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo's pivotal STRIDE study misses endpoints; company cuts 90% workforce, explores strategic alternatives
--------------------------------------------------------------------------------

- STRIDE trial of mavodelpar in primary mitochondrial myopathy failed primary and secondary efficacy endpoints.
- Company suspended all mavodelpar development and reduced workforce by approximately 90%.
- Q4 2023 net loss $23.6M ($0.70/share); full-year net loss $77.4M ($2.52/share).
- Cash, equivalents, and short-term investments $103.0M at Dec 31, 2023; expects ~$82.0M at March 31, 2024.
- Retained independent financial advisor to evaluate strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017024038003/0000950170-24-038003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017024038003/rphm-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer